News | July 15, 2022
Novavax statement on EMA Nuvaxovid label update related to allergic reaction
Novavax’ clinical development program reported no severe allergic reactions
Novavax’ clinical development program reported no severe allergic reactions
Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Younger Indians have a 10 times higher rate of heart attack
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
